Lu Zhihao, Chen Yang, Liu Dan, Jiao Xi, Liu Chang, Wang Yakun, Zhang Zizhen, Jia Keren, Gong Jifang, Yang Zhimin, Shen Lin
Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Peking University Cancer Hospital and Institute, Beijing, China.
National Center for Drug Evaluation, National Medical Products Administration, Beijing, China.
Nat Med. 2023 Dec;29(12):3022-3032. doi: 10.1038/s41591-023-02655-3. Epub 2023 Dec 12.
The rising cancer incidence rate in China poses a substantial public health concern, although there have been remarkable improvements in the country's cancer mortality and survival rates. In this Review, we outline the current landscape and future directions of cancer care and research in China. We discuss national screening programs and strategies for cancer detection and delve into the evolving landscape of cancer care, emphasizing the adoption of multidisciplinary, comprehensive treatment and precision oncology. Additionally, we examine changes in drug research and development policies that have enabled approval of new drugs. Finally, we look to the future, highlighting key priorities and identifying gaps. Effectively addressing challenges and seizing opportunities associated with cancer research in China will enable the development of targeted approaches to alleviate the global burden of cancer.
尽管中国的癌症死亡率和生存率已有显著改善,但该国不断上升的癌症发病率仍是一个重大的公共卫生问题。在本综述中,我们概述了中国癌症护理与研究的现状及未来方向。我们讨论了国家癌症筛查计划和癌症检测策略,并深入探讨了不断变化的癌症护理格局,强调采用多学科、综合治疗和精准肿瘤学。此外,我们研究了使新药得以获批的药物研发政策变化。最后,我们展望未来,突出关键优先事项并找出差距。有效应对与中国癌症研究相关的挑战并抓住机遇,将有助于制定有针对性的方法来减轻全球癌症负担。